A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy

Gareth AD Hardy†1, Nesrina Imami†1, Mark R Nelson2, Ann K Sullivan2, Ron Moss3, Marlén MI Aasa-Chapman4, Brian Gazzard2 and Frances M Gotch*1

Address: 1Department of Immunology, Imperial College London, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK, 2Department of HIV/GU Medicine, Imperial College London, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK, 3Immune Response Corporation, Carlsbad, CA, USA and 4Wohl Virion Centre, Windeyer Institute of Medical Sciences, UCL, London, W1T 4JF, UK

Email: Gareth AD Hardy - gareth.hardy@case.edu; Nesrina Imami - n.imami@imperial.ac.uk; Mark R Nelson - sandra.mead@chelwest.nhs.uk; Ann K Sullivan - ann.sullivan@chelwest.nhs.uk; Ron Moss - shotdoc92130@yahoo.com; Marlén MI Aasa-Chapman - m.aasa-chapman@ucl.ac.uk; Brian Gazzard - eileen.witney@chelwest.nhs.uk; Frances M Gotch* - f.gotch@imperial.ac.uk

* Corresponding author †Equal contributors

Abstract

Background: Fully functional HIV-1-specific CD8 and CD4 effector T-cell responses are vital to the containment of viral activity and disease progression. These responses are lacking in HIV-1-infected patients with progressive disease. We attempted to augment fully functional HIV-1-specific CD8 and CD4 effector T-cell responses in patients with advanced chronic HIV-1 infection.

Design: Chronically infected patients with low CD4 counts T-cell counts who commenced antiretroviral therapy (ART) were subsequently treated with combined interleukin-2 and therapeutic vaccination.

Methods: Thirty six anti-retroviral naive patients were recruited and initiated on combination ART for 17 weeks before randomization to: A) ongoing ART alone; B) ART with IL-2 twice daily for 5 days every four weeks starting at week 17 for 3 cycles; C) ART with IL-2 as in group B and Remune HIV-1 vaccine administered once every 3 months, starting at week 17; and D) ART with Remune vaccine as in group C. Patients were studied for 65 weeks following commencement of ART, with an additional prior 6 week lead-in observation period. CD4 and CD8 T-cell counts, evaluations of HIV-1 RNA levels and proliferative responses to recall and HIV-1 antigens were complemented with assessment of IL-4-secretion alongside quantification of anti-HIV-1 CD8 T-cell responses and neutralizing antibody titres.

Results: Neither IL-2 nor Remune™ vaccination induced sustained HIV-1-specific T-cell responses. However, we report an inverse relationship between HIV-1-specific proliferative responses and IL-4 production which continuously increased in patients receiving immunotherapy, but not patients receiving ART alone.

Conclusion: Induction of HIV-1-specific cell-mediated responses is a major challenge in chronically HIV-1-infected patients even when combining immunisation with IL-2 therapy. An antigen-specific IL-4-associated suppressive response may play a role in attenuating HIV-specific responses.
Background

Immune recovery subsequent to antiretroviral therapy (ART) often appears to be partial and does not comprise the HIV-1-specific CD4 or CD8 T-cell proliferative and IL-2-producing responses that are associated with protection from disease progression [1-5]. These potentially protective HIV-1-specific T-cell responses [6-9], become dysfunctional and exhausted with progressing disease. A number of approaches attempt modulation of cell-mediated responses, including therapeutic immunisation [2,10-12]. Remune™ is a whole, gp120-depleted, inactivated, HIV-1 immunogen in incomplete Freund's adjuvant (IFA) prepared from the recombinant primary isolate HZ-321 [13] (clade A envelope, clade G gag). Clinical trials of intramuscular (I/M) Remune™ including one phase III [14], have failed to demonstrate increases in disease-free survival time despite Remune’s™ induction of HIV-1-specific CD4 T-cell responses [15]. Sub-group analysis failed to demonstrate any consistent effects on viral loads or CD4 counts [16]. Despite this, Remune™ may delay disease progression and reduce development of antiretroviral resistance [17].

Sub-cutaneous (S/C) interleukin (IL)-2, administered with ART, increases CD4 T-cell numbers [18-21] and recall antigen-specific CD4 lymphocyte proliferation [22,23]. However timing may be crucially important to the induction of cell-mediated responses [24]. We have previously shown that IL-2 administration subsequent to immunization was associated with boosted responses to the antigen in question, suggesting a therapeutic role for IL-2 in enhancing proliferative T-cell responses in HIV-1 infection [2,25].

We investigated the ability of Remune™ and IL-2, combined and separately, to induce HIV-1-specific CD4 and CD8 T-cell responses in chronically HIV-1-infected patients on ART in an observational, open-label, randomized, pilot study. We also assessed antigen-specific IL-4 release as this cytokine plays a role in balance and/or suppression of cell-mediated responses [26,27]. We report here evaluation of specific T-cell proliferation, antigen-specific IL-4 release, CD8 T-cell IFN-γ responses and neutralizing antibody titres, in order to comprehensively describe the specific immune response relevant to control of viral replication.

Methods

Patients and Study Design

In this observational, phase I, pilot study conducted at Chelsea and Westminster Hospital, London, 36 antiretroviral-naïve patients were initiated on ART at week 0, which was continued for the duration of the study. ART comprised 2 nucleoside analogues and one protease inhibitor or non-nucleoside reverse transcriptase inhibitor. At week 17 patients were randomized to receive immunotherapy with IL-2 and/or therapeutic immunisation with a gp120-depleted whole inactivated HIV-1 immunogen. Sufficient Remune™ was donated for use in 20 patients by Immune Response Corporation (IRC), Carlsbad, CA, USA. Patients were randomized at week 17 only if their viral load was <50 copies ml/plasma and CD4 T-cell count was ≥300 cells/µl blood at week 16. Treatment groups for randomization were as follows: A) ART alone (n = 9); B) ART plus IL-2 (Proleukin™) (n = 11); C) ART plus IL-2 and Remune™ (n = 7); and D) ART plus Remune™ (n = 9). IL-2 (5 × 10^6U) was administered S/C, twice daily, for 5 days at weeks 17, 21 and 25. 100 µg Remune™ was administered I/M at weeks 17, 29, 41 and 53. Laboratory analysis was conducted at weeks -6, -3 and 0 before ART, and weeks 1, 2, 4, 8, 16, 17, 21, 25, 29, 41, 53 and at study completion at week 65. The primary outcome was induction of positive changes in lymphocyte proliferative responses to HIV-1 antigens. In addition to the main study time points, a further sub-study of viral loads and lymphocyte subset numbers was conducted in a sub-set of patients (n = 15) receiving IL-2 in groups B and C on the 5th day of each IL-2 cycle, i.e. at weeks 18, 22 and 26. This sub-study was initiated after the main study had begun and included all patients receiving IL-2 in groups B and C from the date of its inception. Appropriate regulatory approval was granted by Riverside Ethics Committee and patients gave written informed consent.

Separation of PBMCs

PBMC were separated from whole blood by density gradient centrifugation and cultured in RPMI-1640 with NaCO₃ (Sigma, Poole, UK) and 100 IU/ml penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine supplemented with 10% human AB plasma (all Sigma).

Viral Load and Lymphocyte Subsets

Plasma viral load was measured using the Bayer HIV-1 RNA 3.0 assay (bDNA) (lower limit 50 copies/ml) (Bayer Diagnostics, Newbury, UK). Whole blood lymphocytes were counted with monoclonal antibodies to: CD3, CD4, CD8, and CD45 (Tetra One, Beckman Coulter, High Wycombe, UK) on an Epics XL-MCL flow cytometer (Beckman Coulter).

Recall and HIV-1 antigens

Recombinant HIV-1 and recall antigens (Medical Research Council Centralised Facility for AIDS Reagents, National Institute for Biological Standards and Controls, Potters Bar, UK) were used as described previously [2], at a final concentration of 10 µg/ml Remune™ and its native p24 (IRC, Ca) were used at 3 µg/ml [28].
Lymphocyte Proliferative Assays
Proliferation assays and supernatant collection for IL-4 assessment were conducted as previously described [2]. Stimulation indices (SI) for triplicates (standard error <15%) were calculated as antigen-stimulated β-particle counts per minute (cpm)/no antigen cpm. A positive response was regarded as a SI >5.

Measurement of Cytokine Production
IL-4 bioassays were carried out as previously described [2] using IL-4 (CT.h4S) dependent cell lines. Briefly, IL-4 was measured in culture supernatants of HIV-1 antigen stimulated proliferation assays. Proliferation of the IL-4-dependent cell line CT.h4S was measured by incorporation of tritiated thymidine. Results are presented as IL-4 driven cpmp.

Delayed hypersensitivity (DTH) tests to Remune™
In vivo delayed-type hypersensitivity (DTH) skin tests to Remune™ antigen were performed to assess HIV-1-specific cell-mediated immune responses as described elsewhere [29] in all patients at weeks 17, 29 and 53.

HLA-typing
HLA haplotypes of patients were assessed by PCR-SSP [30].

IFN-γ ELIspot assays
IFN-γ ELIsots were conducted as described previously [31]. Briefly, 2.5 × 10⁶ PBMC from individual patients who had been tissue typed were cultured with or without 10 μg/ml of appropriate HLA-restricted peptides or PHA (positive control) in 96-well anti-IFN-γ (Mabtech, Stockholm, Sweden) coated PVDF-backed plates (Millipore, Watford, UK). After overnight incubation IFN-γ spot-forming cells (SFC) were detected according to the manufacturer’s instructions (Mabtech).

Neutralisation assays
Immunoglobulin (Ig)G was purified from patient and HIV-1 negative plasma using the MAbTrap kit (Amersham Biosciences, Little Chalfont, UK), and quantified by Protein Assay (Bio-Rad, Munich, Germany). Two-fold serial dilutions of purified IgG, from 1 mg/ml, were incubated with 100 focus forming units (FFU) of HIV-1SF162 for 1 hr at 37°C and then plated onto NP2/CD4+ cells. Infection was detected after 48 hrs by p24-immunostaining, as detailed before [32]. The percentage reduction of infection was calculated: 100 × (1-(mean FFU with patient IgG)/(mean FFU with seronegative IgG at 1 mg/ml)).

Statistical Analysis
Changes in lymphocyte subsets and viral load between week 0 and 16, weeks 0 and 65 and weeks 16 and 65, were assessed using the Wilcoxon Signed Rank test. Proliferative stimulation indices, between and within subject weeks 0 to 17, weeks 17 to 65 and weeks 0 to 65, adjusted separate slopes were estimated for each study arm with 95% confidence interval. Differences in overall viral load from week 18–26, between groups B and C were assessed using the Pearson Chi-squared test.

Results
Patient demographics
Fifty two anti-retroviral naïve patients were screened for this study which was carried out at the Chelsea and Westminster Hospital, London over a six year period. Of the screened patients 16 dropped out prior to randomisation at week 17. All the remaining 36 patients who were randomised completed the study. The mean age of patients at study entry was 38.75 years. There was one female patient (2.78%) and 100% of patients were of white European ethnicity.

Viral loads and CD4 T-cell counts
Median viral loads and CD4 T-cell counts for each group are depicted in Figure 1. The median week 0 viral load for all patients was 88,699 copies/ml plasma (range 50–779,254). The median absolute CD4 T-cell count was 294 cells/μl whole blood (range 76–551). Nineteen of 36 patients (53%) had CD4 T-cell counts below 300 cells/μl at pre-ART time points.

By week 17 the median viral load in all groups was less than 50 copies. All patients, except 5 (one in Group A, three in Group B, one in group D), maintained viral suppression at the main study time points from week 17 onwards while receiving ongoing ART. One patient in Group C (patient 11) elected to discontinue ART at week 47 causing subsequent rebound in viraemia. At week 17 the median CD4 T-cell count in each complete group was as follows: Group A, 456 cells/μl (range 261–673) (Figure 1A); Group B, 377 cells/μl (range 81–742) (Figure 1B); Group C, 468 cells/μl (range 306–680) (Figure 1C); Group D, 337 cells/μl (range 289–702) (Figure 1D). IL-2-induced increases in absolute CD4 T-cell counts are also apparent in groups B and C. By week 65 these values were 602 cells/μl (range 300–918) for Group A, 731 cells/μl (range 253–1025) for Group B, 619 cells/μl (range 358–1404) for Group C and 505 cells/μl (range 345–768) for Group D.

Lymphocyte proliferation to HIV-1 antigens
HIV-1-specific proliferative responses increased transiently for many patients. Regression analysis of these responses revealed no significant changes in group A (Fig. 2A). In group-B from week 0 to 65 a significant increase in
the np24 response \( (p = 0.005) \) was observed (Fig. 2B). In group C no increase in HIV-1-specific proliferative responses were seen (Fig. 2C). Of note was an outstanding response to Remune™ with an SI of 95 at week 65 for patient 11 in this group (data not shown) coincident with rebound viraemia (152,536 copies/ml) following self-imposed ART discontinuation. In group D a positive regression was seen in responses to Nef \( (p = 0.004) \) and whole Remune™ antigen \( (p = 0.005) \) from week 0 to 65. The only response which significantly increased between week 17 and 65 in any group was the p24 response in group D \( (p = 0.039) \). Patient 8 in this group demonstrated a very large response to Remune™ (SI = 261) and np24 (SI = 144) at week 29 following breakthrough of resistant virus at week 25 (6,315 copies/ml) (data not shown). No other substantial increases in responses occurred between week 17 and 65 for any group or at any time point between the groups.

**In vivo delayed type hypersensitivity reactions to Remune™**

Induration size of hypersensitivity reactions to Remune™ did not become positive (>9 mm diameter) in any patient at any of the time points tested (weeks 17, 29 and 53).

**Lymphocyte proliferation to recall antigens**

Baseline to week 16 T-cell responses have been described in detail previously [1]. Regression analysis revealed significant increases in recall responses in all groups between week 0 and 65 (Fig. 2E–H), predominantly for the persistent recall antigens: For group A (Figure 2E) responses to CMV and Candida significantly increased \( (p = 0.027 \text{ and } p = 0.006 \text{ respectively}) \); for group B (Figure 2F) HSV responses significantly increased \( (p = 0.007) \), CMV responses increased \( p = 0.002 \) and Candida responses increased \( p = 0.0006\); in group C (Figure 2G) CMV and Candida responses increased \( p = 0.002 \text{ and } p = 0.007 \text{ respectively})\); in group D (Figure 2H) HSV and CMV responses significantly increased \( p = 0.002 \text{ and } p = 0.001\). Responses to transient antigens were less apparent. In group A PPD and tetanus responses showed significant positive regressions over the 65 weeks \( (p = 0.018 \text{ and } p = 0.018 \text{ respectively})\); in group B only the PPD response regression curve was significant \( (p = 0.044)\); and in group C only the tetanus response was significant \( p = 0.0003)\). There were no significant differences in recall responses between treatment groups.

**HIV-1-specific IL-4 production**

Antigen-specific IL-4 production may be associated with suppression of proliferative responses and dampening of inflammatory immune responses. Therefore we measured
Figure 2
Mean HIV-1-specific lymphocyte proliferative responses (left-hand panel) with the times of IL-2 and Remune™ administration, showing responses for group A (A), group B (B), group C (C) and group D (D) and mean recall-specific lymphocyte proliferative responses (right-hand panel) with the times of IL-2 and Remune™ administration, for group A (E), group B (F), group C (G) and group D (H). The scale of HIV-1-specific responses is displayed as half the magnitude of that for recall responses.
IL-4 production in proliferation assay culture supernatants in response stimulation with each HIV-1 antigen, as previously described [1]. Significant increases in HIV-1-specific IL-4 production from weeks 17 to 65 were observed in response to p24 in group B (p = 0.023), and group C (p = 0.032) and in response to gp120 in group D (p = 0.037) (Fig. 3A). HIV-1-specific IL-4 production did not significantly increase in group A (data not shown).

We observed an apparent relationship between IL-4 production and loss/lack of proliferation in 17 of 28 patients tested, distributed evenly between groups, evident from week 0 to 16 and week 17 to 65. Patient 11 (group C) is shown as an example, where HIV-1-specific proliferative responses to p24, gp120, nef and Remune™ are high at week 0 to 16 and week 17 to 65. Patient 11 (group C) is an exception, although this patient had high baseline responses and by week 65 had discontinued ART causing considerable rebound viraemia, concomitant with strong HIV-1-specific lymphocyte proliferative responses as detailed above.

**CD8 T-cell IFN-γ responses to HLA class I restricted peptides**

Where possible, we investigated CD8 T-cell IFN-γ production in response to characterised HLA class I restricted peptides (listed in Table 1), by ELISpot assay using cryopreserved PBMCs. As reported previously [15] Remune™ did not induce increases in CD8 T-cell responses. Although fluctuations occurred in CD8 T-cell IFN-γ responses these were not sustained and could not be attributed to ART or immunotherapy. Summary data is presented from week 0, following ART alone at week 16 and at week 65 in Table 2. Assays in which responses were not observed to the positive control, PHA, were considered to have failed, as denoted by "F". Of note is the observation that no patient in groups B, C or D demonstrated an increase in responses between week 16 and week 65. Patient 11 is an exception, although this patient had high baseline responses and by week 65 had discontinued ART causing considerable rebound viraemia, concomitant with strong HIV-1-specific lymphocyte proliferative responses as detailed above.

**Discordant viraemia between patients receiving IL-2 with or without Remune™**

Secondary to the main study protocol, further viral load and lymphocyte subset analysis was conducted at additional time points – week 18, week 22 and week 26 – for a sub-group of 15 patients receiving IL-2 in groups B (n = 9) and C (n = 6) on the last day of each IL-2 cycle. Small, transient elevations in HIV-1 RNA load were apparent on 12 occasions for 7 of 9 (78%) patients in group-B, and 2 of 6 patients (33%) in group-C. All these viral load elevations had spontaneously resolved by the next viral load test 3 weeks later at weeks 21, 25 and 29. The difference in occurrence of these viral load elevations remains evident when comparing the median viral loads for all the patients in groups B and C as shown in Fig. 1B and 1C.

The median viral load change (from 50 copies/ml) for the patients who had day 5 viral load measurements in group B were 23.5 copies/ml, 53 copies/ml and 0 copies/ml at the end of each IL-2 cycle. In comparison the median change in viral load for patients in group C who had day 5 viral load measurements was 0 at each time point. Change in viral load was not significantly different when comparing the sub-study patients in group B with those in group C, at any of the 3 individual IL-2 day 5 time points. However, when taking all three day 5 time points together for each group, comparison between the two groups revealed a trend towards significance (p = 0.071, Pearson Chi-Squared).

**Neutralising antibody responses in discordant virologic responders**

As Remune™ displays the transmembrane (gp41) envelope antigen with strong neutralization epitopes [33-35], it may prime neutralizing antibodies to new epitopes. We tested the ability of plasma IgG from patients in Group C who did not experience day 5 viral blips to neutralize HIV-1SF162 at weeks 0, 16 and 65. There was no effect of immunotherapy or ART on virus neutralization (data not shown).

**Discussion**

In this pilot study of combined immunotherapy with the therapeutic HIV-1 vaccine Remune™ and subcutaneous IL-2 in the context of ART, neither IL-2 nor Remune™ immunisation conferred any substantial benefits to the effect of ART with regard to HIV-1-specific CD4 or CD8 T-cell responses, or neutralising antibodies. For the majority of these chronically HIV-1-infected patients responses to HIV-1 antigens remained negligible and there was little difference between the four immunotherapy arms. Possible reasons for this could be: the low CD4 T-cell counts of these patients when ART was initiated resulting in protracted immunosuppression and/or clonal dysfunction; a need for longer duration of ART before immunotherapeutic intervention, thus allowing greater immune recovery; the permanent depletion of HIV-1-specific CD4 T-cells by direct HIV-1 infection; and/or the timing of IL-2 therapy with immunisation which may have important consequences for induction or suppression of induced responses.

Previous Remune™ studies which induced proliferative responses comprised patients with higher pre-ART mean CD4 T-cell counts of 617 cells/μl [36] and 700 cells/μl blood [15]. The mean in this study was 303 cells/μl. 53% of these patients had CD4 nadirs below 300 cells/μl. Immune reconstitution in patients who initiate ART with low CD4 T-cell counts is impaired compared to those who initiate ART with higher CD4 T-cell counts [37,38]. The ability to respond to immunisation is also dependant on
Figure 3
HIV-1-specific IL-4 production and lymphocyte proliferative responses. Significant increases in CT.h4S delta cpm in response to HIV-1-specific IL-4 production were seen over the week 17–65 period (A) for groups B (ART + IL-2), C (ART + IL-2 + Remune™) and D (ART + Remune™), but not for group A (ART alone) (data not shown). Patient 11 is shown as an example of an inverse relationship between lymphocyte proliferative stimulation index (SI) (B) and IL-4 production as delta cpm (C) which was evident for 17 of 28 patients who were assessed for IL-4 production.
### Table 1: HLA class I restricted peptides used for IFN-γ ELISpot assays

| Peptide | Protein | Sequence | HLA-restriction |
|---------|---------|----------|-----------------|
| **Gag** |         |          |                 |
| g1      | p17 (71–79) | GSEELRLSY | A1              |
| g2      | p17 (77–85) | SLYNTVATL | A*0201          |
| g3      | p17 (20–28) | RLPGGKKK  | A3              |
| g4      | p24 (217–227) | ACQVGGPGHK | A11            |
| g5      | p17 (84–92) | TLYCVHQRI | A11            |
| g6      | p17 (28–36) | KYKLKHIWV | A24            |
| g7      | p24 (35–43) | EVIPMFSAL | A26            |
| g8      | p24 (16–23) | SPRTLNAW  | B7              |
| g9      | p17 (74–82) | ELRSLYNTV | B8              |
| g10     | p24 (197–205) | DCKTILKAL | B8              |
| g11     | p17 (93–101) | EIKDTEKAL | B8              |
| g12     | p17 (24–31) | GGGKKSYYK | B8              |
| g13     | p24 (131–140) | KRWILGLNK | B27            |
| g14     | p17 (36–44) | WASRELRF  | B35^            |
| g15     | p17 (124–132) | NSSKVSQNY | B35^            |
| g16     | p24 (122–130) | PPIPVGDY | B35^            |
| g17     | p24 (174–184) | AEQSAQDVKNW | B44      |
| g18     | p24 (83–92) | VHPVHAGPIA | B55          |
| g19     | p24 (108–117) | TSTLQEIQGW | B57^          |
| g20     | p24 (176–184) | QASQEVKNW | B57^          |
| g21     | p24 (15–23) | ISRRTLNAW | B57^          |
| g22     | p24 (32–40) | FSPEVIPMF | B57^          |
| g23     | p17 (92–101) | IEIKDTEKAL | B61            |
| **Pol** |         |          |                 |
| p1      | RT (309–317) | ILKEPVHG | A*0201          |
| p2      | RT (179–187) | VYIQYMDDL | A2              |
| p3      | RT (485–493) | ALQDSSLEV | A2              |
| p4      | RT (341–350) | IYQEPKLNK | A11            |
| p5      | RT (158–166) | AIFQSSMTK | A11            |
| p6      | IN (179–188) | AVFIHNFKRR | A11            |
| p7      | RT (448–457) | RETKLGKAGY | A29            |
| p8      | RT (392–401) | PIQKETWETW | A32            |
| p9      | RT (18–26) | GPKVKQWPL | B8              |
| p10     | RT (175–183) | HPDIVVY | B35^            |
| p11     | RT (156–164) | SPAIQSQSM | B35^            |
| p12     | RT (432–441) | EPAIGAATFY | B35^          |
| p13     | RT (203–212) | EELROHLRW | B44            |
| p14     | RT (397–406) | TWETWVETYW | B44            |
| **Nef** |         |          |                 |
| n1      | nef (180–189) | VLEWRFDSRL | A2              |
| n2      | nef (73–82) | QVPLRPMTYK | A11            |
| n3      | nef (75–82) | PLRPMTYK | A11            |
| n4      | nef (84–92) | AVDLHFLK | A11            |
| n5      | nef (128–137) | TPGPGVRYPL | B7              |
| n6      | nef (90–97) | FLKEKQGL | B8              |
| n7      | nef (13–20) | WPTVRERM | B8              |
| n8      | nef (135–143) | YPLTDFGWCY | B18/B49        |
| n10     | nef (186–193) | DSRQAFHH | B35^            |
| n11     | nef (74–84) | VPLRPMTY | B35^            |
| n12     | nef (116–125) | HTQGYPDWQ | B57^            |
| n13     | nef (92–100) | KEKGGLEG | B61            |

Peptides were identified from the NIH HIV Molecular Immunology Database website [50]. References for each peptide are also available at this website. RT (reverse transcriptase antigen), IN (integrase antigen). A^HLA B35 is associated with rapid progression in HIV-1 infection. B^HLA B57 is associated with slow/non progression in HIV-1 infection.
Table 2: Patient HLA types and ELISpot results, showing the sum of delta (background subtracted) IFN-γ spot forming cells (SFC) at weeks 0, 16 and 65 for each patient for whom ELISpot analysis was possible.

| Patient | HLA type (peptides used) | Sum of Δ IFN-γ SFC/10^6 PBMC |
|---------|--------------------------|-------------------------------|
|         |                          | Week 0 | Week 16 | Week 65 |
| Group A | Gag | Pol | Nef | Gag | Pol | Nef | Gag | Pol | Nef |
| 1       | A1, (g1) | b2, (p1, p2, p3, n1) | B7 (g8, n2) | B18 (n8) | B67 (n8) | B14 (p13, p14) | 20 | 20 | 260 |
| 16      | A2, (g2, p1, p2, p3, n1) | B44 (g17, n3, p14) | F | F | 70 | 60 | 30 | 230 | 280 | 370 |
| 36      | A11, (g4, g5, p5, n2) | A9, (none identified) | B35a, (g14, p10) | B61 (g23, p15, n13) | 670 | 470 | 295 | 910 | 405 | 1280 | 370 |
| 52      | A2, (g2, p2, n1) | A11, (g5, p5) | B27, (n9) | B35a, (g14, p10) | 80 | 190 | 30 | F | F | 290 |

| Group B | Gag | Pol | Nef | Gag | Pol | Nef | Gag | Pol | Nef |
|---------|--------------------------|-------------------------------|
| 7       | A2, (g2, p2, n1) | A24, (g6) | B55, (g18) | B57a (g19, 20, 21, g22) | 50 | 50 | 75 | 130 | 70 | 25 | 185 | 135 | 115 |
| 35      | A3, (g3) | A32, (p8) | B7 (g8, n5) | F | F | F | 490 | 50 | 130 | 190 | 30 | 20 | 450 |
| 57      | A1, (g1) | B8 (g9, g10, g11, p9, n6, n7) | F | F | F | 3820 | 3140 | 2990 | 90 | 50 | 20 | 2820 | 2760 | 960 |
| Group C | Gag | Pol | Nef | Gag | Pol | Nef | Gag | Pol | Nef |
| 4       | A1, (g1) | A26, (g7) | B27, (n9) | B57a (g19, 20, 21, g22, n12) | 220 | nd | 50 | 130 | nd | 40 | 520 | nd | 60 |
| 11      | A2, (g2, p1, p2, p3, n1) | B35, (g14, g15, g16, p10, p11, p12, n10, n11) | 3820 | 3140 | 2990 | 90 | 50 | 20 | 2820 | 2760 | 960 |
| 14      | A1, (g1) | A2, (g2, p1, p2, p3, n1) | B57a (g19, 20, 21, g22, n12) | F | F | F | 1140 | 130 | 20 | 100 | 30 | 70 |
| 34      | A3, (g3) | A29, (p7) | B35a, (g14, g15, p10, n10) | B44 (g17, p13, p14) | 320 | 100 | 0 | F | F | F | 520 | 80 | 10 |
| Group D | Gag | Pol | Nef | Gag | Pol | Nef | Gag | Pol | Nef |
| 13      | A2, (g2, p1, p2, n1) | A11, (g4, p4, n2) | B8, (g7, p5, n6) | B62 (none identified) | 50 | 20 | 70 | 730 | 1890 | 1190 | 390 | 640 | 240 |
| 22      | A1, (g1) | A2, (g2, p2, n1) | B7, (g8, n5) | B57a (g14, g15, p10, n11) | 270 | 80 | 120 | F | F | 60 | 40 | 260 |

F denotes assay failure. IFN-γ (interferon-gamma), PBMC (peripheral blood mononuclear cells), SFC (spot forming cells). *HLA B35 is associated with rapid progression in HIV-1 infection. **HLA B37 is associated with slow/non progression in HIV-1 infection.
higher CD4 T-cell count nadirs and earlier initiation of ART [39].

The fate of missing HIV-1-specific CD4 T-cell responses is unclear. HIV-1 preferentially infects and deletes many HIV-1-specific CD4 T-cells [7], while some remain detectable, expressing IFN-γ, though unable to proliferate or express IL-2 [40,41]. The significant increase in HIV-1-specific IL-4 production from weeks 17 to 65 in group B (p24), C (p24) and D (gp120) could indicate clonal dysfunction in these patients. Only group A (ART alone) had no increase in HIV-1-specific IL-4 production. Thus immunotherapy in these patients appears to be associated with increasing levels of HIV-1-specific IL-4 production. IL-4, an anti-inflammatory type-2 cytokine, has a suppressive effect on lymphocyte proliferation [26,42]. The observation in a number of patients that HIV-1-specific IL-4 increases when proliferative responses diminish may indicate a mechanism by which clonal proliferation remains suppressed, although this needs further investigation. We previously found a balanced IL-4/IL-2 phenotype in HIV-1-specific CD4 T-cell responses in patients who remain disease free [27]. While IL-4 expression by HIV-1-specific CD4 T-cells may be thought of as a pathological anti-proliferative effect, it must be considered that this phenotype could be protective, by dampening immune activation and quashing viral replication. This relationship requires further investigation.

Despite the lack of induced HIV-1-specific T-cell responses in these patients we report significant increases in recall antigen proliferative responses, particularly for persistent antigens. These increases were largely evident between week 0 and 65 with no differences between groups, suggesting immunotherapy was ineffective in this respect. While some significant increases in proliferative responses to HIV-1 antigens were apparent from week 0 to 65 (group B and D), the same cannot be said regarding the immunotherapy period between weeks 17 and 65. Nor were there any significant differences in responses between groups. These results suggest that any improvements were singularly attributable to duration of ART.

Of note is one patient in group B, vaccinated with tetanus 4 weeks before receiving IL-2. High tetanus-specific proliferation was enhanced and sustained by subsequent IL-2, as reported separately [25]. In contrast a second patient received tetanus vaccination after IL-2 and did not respond. These responses may be dependent on administration of IL-2 subsequent to antigen priming, during T-cell contraction. Animal models demonstrate IL-2 administration during T-cell contraction enhances and prolongs responses, unlike co-administration of IL-2 with antigen when the survival of responding T cells is abrogated [24]. Our protocol and others that also achieved limited induction of responses [43] utilized a co-administered model. Future trials will address such important issues.

We observed low-levels of transient self-limiting viraemia resulting from IL-2 therapy as previously reported [44]. Despite the lack of detectable cell-mediated responses induced by immunotherapy in these patients, the transient viral load blips we have reported appear to occur less in patients receiving IL-2 when administered with Remune™ in group C, with a trend towards significance (p = 0.071). Larger group sizes may have revealed a stronger relationship between Remune™ and protection from IL-2 induced transient viraemia, but this pilot study was not powered for such observations. This possible effect of Remune™ was not due to induction of neutralising antibodies, by the display of potentially sensitive epitopes on gp41 resulting from the removal of gp120 from Remune™ [45]. We have separately reported the induction of antibody responses against HLA-B62 and HLA-DR4 in some of these patients who received Remune™ immunisation [46], as Remune™ contains these antigens derived from the HUT-78 cell line in which it is grown. Group sizes are too small in this study to determine whether such responses may have played a role in potential protection from viral blips in group C.

**Conclusion**

Combined Remune™ and IL-2 with ART in advanced HIV-1 infection conferred no immunological benefits to ART. Taking together the absence of induced HIV-1-specific lymphocyte proliferative responses, CD8 T-cell IFN-γ responses and in vivo DTH responses these results imply that induction of renewed HIV-1-specific cell-mediated responses by therapeutic immunisation, even when supplemented with IL-2, is extremely problematic in patients who initiate ART with lower CD4 T-cell counts. Although a recently reported clinical trial of the vCP1433 canary pox-based therapeutic vaccine elicited p24-specific responses which were significantly associated with time off therapy in a subsequent treatment discontinuation protocol, these responses also remained transient, diminishing at study end [47]. This underscores the difficulties in inducing protective immune responses by therapeutic immunisation of chronically infected patients. Furthermore immunological protection in chronically infected individuals may be best conferred by autologous virus, as opposed to vaccine derived antigens as found with the vCP1452 canary pox vaccine [48] to which T-cell responses may in fact be associated with more rapid viral rebound following treatment interruptions [49]. In our study we saw the greatest proliferative responses to HIV-1 antigens in patients who experienced virological rebounds, demonstrating that autologous virus induces greater responses, albeit transiently, than immunisation or IL-2 therapy.
In these chronically infected treated patients, we found that immunotherapy was associated with increasing HIV-1-specific IL-4 production, which appears to negatively impact proliferative responses. HIV-1-specific IL-4 production may result from a general dysfunction of HIV-1-specific CD4 T-cells with pathological implications for induction of HIV-1-specific responses. We suggest that these results underscore the importance of early initiation of ART. As Remune™ may have positive effects in less advanced patients [17], we suggest further investigations, with or without cytokine adjuvants, be conducted in patients for whom extensive immunological damage has been prevented with earlier initiation of ART.

Abbreviations
ART (antiretroviral therapy), CMV (Cytomegalovirus), cpm (counts per minute), DNA (Deoxyribonucleic Acid), HIV-1 (Human Immunodeficiency Virus type-1), HLA (Human Leukocyte Antigen), HSV (Herpes Simplex Virus), IgG (Immunoglobulin G), IFN (Interferon), IL (Interleukin), I/M (Intramuscular), PBMC (Peripheral Blood Mononuclear Cells), PCR (Polymerase Chain Reaction), RNA (Ribonucleic Acid), S/C (subcutaneous), SI (Stimulation Index).

Competing interests
The author(s) declare that they have no competing interests.

Authors' contributions
All authors have read and approved the final version of this manuscript. GH, FG, NI and BG conceived the study. GH and BG participated in the application for government and ethical approval, and in co-ordination of the study; he conducted laboratory work and cellular immunological assays, conducted data analysis and Interpretation, and preparation and completion of the manuscript. NI had responsibility for overall management and coordination of the study, she conducted laboratory work and cellular immunological assays, coordinated data analysis and interpretation, and participated in preparation of the manuscript. FG and NI secured funding for the study. FG participated in data analysis and interpretation, and in preparation of the manuscript. RM provided Remune™ vaccine and Remune™ antigen and its native p24 antigen and participated in study design. MAA conducted virus neutralisation assays. BG participated in the design of the study, coordinated application for government and ethical approval, and coordinated patient management. AS undertook patient care and management and participated in study co-ordination, and data interpretation. MN participated in patient care and management and data interpretation.

Acknowledgements
The authors would like to extend their gratitude to The Welcome Trust (Grant numbers 050020 and 058700) and the St Stephen’s AIDS Trust/Cruise 4 Bands for funding. NI and FG were also funded by EU (Grant number LSHP-CT-2004-503487) and MRC (Grant number G0501957). Clade B HIV-1 recombinant antigens were provided by the EU Programme EVA/MRC Centralised Facility for AIDS Reagents, NIBSC, UK (Grants QLK-CT 1999-00609 and G9828102). Remune™ vaccine, Remune™ and native p24 antigens were provided by Ron Moss, at the time of writing with Immune Response Corporation, Carlsbad, CA, USA. We would also like to thank Aine McKnight for contributions to the study and design and implementation of neutralization experiments, Sundhiya Mandalia and Benigno Rodriguez for help with statistical analysis, the routine laboratory staff at the Department of Immunology, the nursing staff, and most importantly the patients at the St Stephen’s Centre, Chelsea and Westminster Hospital, London, UK.

References
1. Hardy GA, Imani N, Sullivan AK, Pires A, Burton CT, Nelson MR, et al.: Reconstitution of CD4+ T cell responses in HIV-1 infected individuals initiating highly active antiretroviral therapy (HAART) is associated with renewed interleukin-2 production and responsiveness. Clin Exp Immunol 2003, 134:98-106.
2. Iman I, Hardy G, Gocht F: Development of immunotherapeutic strategies for HIV-1. Expert Opin Biol Ther 2001, 1:803-816.
3. Jansen CA, Piriou E, De Cuypier JM, van Dort K, Lange JM, Miedema F, van Baarle D: Long-term highly active antiretroviral therapy in chronic HIV-1 infection: evidence for reconstitution of antiviral immunity. Antivir Ther 2006, 11:105-116.
4. Ponteselli O, Kerkhof-Garde S, Notermans DW, Fouadaine NA, Roos MT, Klein MR, et al.: Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. J Infect Dis 1999, 180:76-86.
5. Kalams SA, Goudey PJ, Shea AK, Jones NG, Trocha AK, Ogg GS, Walker BD: Levels of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J Virol 1999, 73:6721-6728.
6. Rosenberg ES, Walker BD: HIV type 1-specific helper T cells: a critical host defense. AIDS Res Hum Retroviruses 1998, 14(Suppl 2):S143-S147.
7. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, et al.: HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002, 417:95-103.
8. Valdez H, Carlson NL, Post AB, Asaad R, Heeger PS, Lederman MM, et al.: HIV long-term non-progressors maintain brisk CD8 T cell responses to other viral antigens. AIDS 2002, 16:1113-1118.
9. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, et al.: Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999, 189:991-998.
10. Garcia F, Lejeune M, Climent N, Gil C, Alcani J, Morente V, et al.: Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis 2005, 191:1680-1685.
11. Kinloch-de Loes S, Hoen B, Smith DE, Autran B, Lampe FC, Phillips AN, et al.: Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 2005, 192:607-617.
12. Levy Y, Durier C, Lascaux AS, Meiffredi V, Galery-Ségard H, Goujard C, et al.: Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS 2006, 20:405-413.
13. Saltik J: Prospects for the control of AIDS by immunizing sero-positive individuals. Nature 1987, 327:473-476.
14. Kahn JO, Cheng DW, Mayer K, Murray H, Lagakos S: Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 × 10(6)/L CD4 T cell counts: A randomized controlled trial. JAMA 2000, 284:2193-2202.
15. Robbins GK, Addo MM, Troupin H, Rathod A, Habeek K, Davis B, et al. Augmentation of HIV-1-specific T helper cell responses in chronic HIV infection by therapeutic immunization. Aids 2003, 17:1121-1126.

16. Turner JL, Kostman JR, Aquino A, Wright D, Szabo S, Bidelow R, et al. The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomized, advisor-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs. HIV Med 2001, 2:68-77.

17. Chantarita W, Sukeepaisarncharoen W, Chandyeying V, Kulpradit S, Israngkura Na Ayudhaya B, Ruppao S, et al. Delayed progression to AIDS in volunteers treated with long-term HIV-1 Immunogen (REMUNE) therapy in Thailand. HIV Med 2004, 5:317-325.

18. Davey RT Jr, Chaitt DG, Albert JM, Piscitelli SC, Kovacs JA, Walker RE, et al. A randomized trial of high- versus low-dose subcutaneous interleukin-2 in patients with advanced HIV disease: the Interleukin-2 In AIDS (IL-2IA) trial. J Infect Dis 1999, 179:849-858.

19. Davey RT Jr, Chaitt DG, Piscitelli SC, Wells M, Kovacs JA, Walker RE, et al. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. N Engl J Med 1995, 333:567-575.

20. Davey RT Jr, Murphy RL, Graziano FM, Boswell SL, Pavia AT, Cancio et al. Increased CD4 T lymphocytes with intermittently courses of subcutaneous interleukin 2 in patients with human immunodeficiency virus infection. A preliminary study. J Infect Dis 1999, 175:781-789.

21. Levy Y, Durier C, Krasievski R, Rabian C, Capinant C, Lascaux AS, Espie S, Borrow P, et al. Induction of HIV-1-specific delayed-type hypersensitivity: a randomized controlled trial. J Immunol 2001, 167:1759-1766.

22. Aasa-Chapman MM, Hayman A, Newton P, Cornforth D, Williams I, Conley AJ, Kessler JA 2nd, Boots LJ, Tung JS, Arnold BA, Keller PM, et al. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2FS, an anti-gp41 human monoclonal antibody. Proc Natl Acad Sci USA 1994, 91:3348-3352.

23. Fikola A, Pomales AB, Yuan H, Korber B, Maddon PJ, Allaway GP, et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995, 69:6609-6617.

24. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001, 75:10892-10905.

25. Valentine FT, Paulino A, Saito A, Holzman RS: Lymphocyte-proliferative responses to HIV antigens as a potential measure of immunological reconstitution in HIV disease. AIDS Res Hum Retroviruses 1998, 14(Suppl 2):S161-166.

26. Lange CG, Valdez H, Medvik K, Asaad R, Lederman MM: CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. Clin Immunol 2002, 102:154-161.

27. Lederman HM, Williams PL, Wu JW, Evans TG, Cohn SE, McCutchan JA, et al. Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected persons who have severe CD4+ cell depletion. J Infect Dis 2003, 188:1794-1803.

28. Lange CG, Lederman MM, Medvik K, Asaad R, Wild M, Kalayan R, Valdez H: Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS 2003, 17:2253-334.

29. Wilson JD, Imani N, Watkins A, Gill J, Hay P, Gazzard B, et al. Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease. J Infect Dis 2000, 182:792-798.

30. Younes SA, Yassine-Diab F, Demouton AR, Boulouasserie R, Grossmann R, Routy JP, Sekaly RP: HIV-1 viremia prevents the establishment of interleukin-2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med 2003, 198:1909-1922.

31. Imani N, Brooksie PA, Lombardi G, Hakooz B, Johns M, Goldman JM, et al. Association between interleukin-4-producing T lymphocyte frequencies and reduced risk of graft-versus-host disease. Transplantation 1998, 65:979-988.

32. Kuekrek H, Schlingmann T, Valdez H, Boehm BO, Pollard RB, Mitsu- yasu R, et al. Differential effect of interleukin-2 treatment on primary and secondary immunizations in HIV infected individuals. AIDS 2005, 19:1967-1974.

33. Sullivan AK, Hardy GA, Nelson PR, Gotch F, Gazzard BG, Imani N: Interleukin-2-associated bloodthrougns induce HIV-1-specific CD4 T cell responses in patients on fully suppressive highly active antiretroviral therapy. AIDS 2003, 17:628-629.

34. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, et al. HIV vaccine design and the neutralizing antibody problem. J Immunol 2006, 175:2337-2343.

35. Page M, Ojugo A, Imani N, Hardy G, Gotch F, Almond N: Specificity of anti-human leukocyte antigen antibody responses after immunization with Remune, an inactivated HIV-1 vaccine. AIDS 2007, 21:375-377.

36. Tubiana R, Carcelan G, Vray M, Mouriin K, Dalban C, Chermak A, et al. Therapeutic immunization with a human immunodeficiency virus (HIV) type 1 recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094). Vaccine 2005, 23:4292-4301.

37. Jacobson MJ, Pat Bucy R, Spritzler I, Saag MS, Eron Jr JF, Coombs RW, et al. Evidence That Intermittent Structured Treatment Interruption, but Not Immunization with ALVAC-HIV vCP1452, Promotes Host Control of HIV Replication: The Results of AIDS Clinical Trials Group 5068. J Infect Dis 2006, 194:623-632.

38. Austran B: Time to ART Resumption following Treatment Interruption Is Shorter for Individuals Immunized with HIV- Recombinant Canarypox Vaccine (vCP1452) Compared to Placebo: The Manon-02 Trial. Conference on Retroviruses and Opportunistic Infections 2007. Abstract 126LB.

39. NIH HIV Molecular Immunology Database. [http://www.hiv.lanl.gov/content/immunology/ctl_search]